|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Atlantic Health System |
|---|---|
| Information provided by: | Atlantic Health System |
| ClinicalTrials.gov Identifier: | NCT00436943 |
Purpose
The researchers hypothesize that smoking cessation counseling improves with the implementation of a smoking status assessment data sheet in routine consults. This is a quality improvement study design to evaluate the impact of the implementation of a more formal smoking status evaluation in a resident/faculty driven outpatient clinic.
| Condition | Intervention |
|---|---|
|
Smoking |
Drug: nicotine replacement therapy and bupropion Behavioral: smoking cessation counseling and referrals |
| Study Type: | Observational |
| Study Design: | Ecologic or Community, Prospective |
| Official Title: | Smoking Cessation Program: A Quality Improvement Trial in a Resident Based Outpatient Clinic |
| Estimated Enrollment: | 900 |
| Study Start Date: | January 2007 |
| Estimated Study Completion Date: | January 2008 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
A
Smokers
|
Drug: nicotine replacement therapy and bupropion
3-6 months
Behavioral: smoking cessation counseling and referrals
Organizational counseling and referrals
|
We hypothesize that smoking cessation counseling improves with the implementation of a smoking status assessment data sheet in routine consults. This is a quality improvement study design to evaluate the impact of the implementation of a more formal smoking status evaluation in a resident/faculty driven outpatient clinic. This will be an observational study in which differences in quality measures will be compared between baseline and re-measurement periods. Population target: 900 patients screened before and after the implementation of the QI intervention. Primary outcome: smoking status evaluation. Secondary Outcome: number of patients advised to quit, plan implementation for smoking cessation, smoking cessation program referrals, number of NRT and bupropion prescription.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Outpatient clinic
Inclusion Criteria:
Contacts and Locations| Contact: Mir A. Mohammad, MD | (973) 885-3187 | mir.mohammad@atlantichealth.org |
| Contact: Leopoldo Segal, MD | (973) 476-8239 | leopoldo.segal@atlantichealth.org |
| United States, New Jersey | |
| Family Health Center at Morristown Memorial Hospital | Recruiting |
| Morristown, New Jersey, United States, 07960 | |
| Contact: Patricia Harris, MD 973-889-6814 patricia.harris@atlantichealth.org | |
| Sub-Investigator: Mir A. Mohammad, MD | |
| Sub-Investigator: Elkin Nunez, MD | |
| Sub-Investigator: Damanpreet Ubhi, MD | |
| Sub-Investigator: Leopoldo Segal, MD | |
| Principal Investigator: | Patricia Harris, MD | Atlantic Health System - Morristown Memorial Hospital |
More Information
| Study ID Numbers: | R06-12-021, Smoking Cessation |
| Study First Received: | February 16, 2007 |
| Last Updated: | January 12, 2009 |
| ClinicalTrials.gov Identifier: | NCT00436943 |
| Health Authority: | United States: Institutional Review Board |
|
smoking cessation nicotine replacement therapy bupropion smoking |
|
Nicotine polacrilex Smoking Dopamine Nicotine Bupropion |
|
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Agonists Molecular Mechanisms of Pharmacological Action Nicotinic Agonists Physiological Effects of Drugs Psychotropic Drugs Cholinergic Agents Pharmacologic Actions |
Habits Autonomic Agents Therapeutic Uses Ganglionic Stimulants Dopamine Agents Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |
